Ofatumumab is not recommended for use within NHS Scotland

[Guest guest]

ish Medicines Consortium (SMC) ~ August 9th

The ish Medicines Consortium (SMC) has advised that ofatumumab (Arzerra®)

is not recommended for use within NHS Scotland for the treatment of chronic

lymphocytic leukaemia (CLL) in patients who are refractory to fludarabine and

alemtuzumab.

The Committee added that interim analysis of a non-randomised, single-arm small

study in a subgroup of patients refractory to fludarabine and alemtuzumab found

that ofatumumab produced a response rate of 58%, but the manufacturer's

justification of the treatment's cost in relation to its health benefits was not

sufficient to gain acceptance by the SMC.

~chris

http://cllcanada.ca